Advertisement

Treatment of Frontotemporal Dementia

  • Richard M. TsaiEmail author
  • Adam L. Boxer
Dementia (E McDade, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Dementia

Opinion statement

Frontotemporal dementia (FTD) encompasses a spectrum of neurodegenerative diseases with heterogeneous clinical presentations and two predominant types of underlying neuropathology. FTD typically comprises three distinct clinical syndromes: behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). FTD also frequently overlaps both clinically and neuropathologically with three other neurodegenerative syndromes: corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS). Each syndrome can be associated with one or more underlying neuropathological diagnoses and are referred to as frontotemporal lobar degeneration (FTLD). Although the various FTD syndromes can substantially differ in terms of clinical symptoms and underlying pathology, the symptoms can be broadly categorized into behavioral, cognitive and motor domains. Currently there are no Food and Drug Administration (FDA) approved therapies for the above syndromes except riluzole for ALS. FTD treatment strategies generally rely on off-label use of medications for symptomatic management, and most therapies lack quality evidence from randomized, placebo-controlled clinical trials. For behavioral symptoms, selective serotonin reuptake inhibitors may be effective, while case reports hint at possible efficacy with antipsychotics or anti-epileptics, but use of these latter agents is limited due to concerns regarding side effects. There are no effective therapies for cognitive complaints in FTD, which frequently involve executive function, memory, and language. Motor difficulties associated with FTD may present with parkinsonian symptoms or motor neuron disease, for which riluzole is indicated as therapy. Compared to idiopathic Parkinson’s disease, FTD-related atypical parkinsonism is generally not responsive to dopamine replacement therapies, but a small percentage of patients may experience improvement with a trial of carbidopa-levodopa. Physical and occupational therapy remain an important corner stone of motor symptom management in FTD. Speech therapy may also help patients manage symptoms associated with aphasia, apraxia, and dysarthria. Recent advances in the understanding of FTLD pathophysiology and genetics have led to development of potentially disease-modifying therapies as well as symptomatic therapies aimed at ameliorating social and behavioral deficits.

Keywords

Frontotemporal dementia Primary progressive aphasia Progressive supranuclear palsy Corticobasal syndrome Treatment Memantine Acetylcholinesterase inhibitor Clinical trials Therapeutics 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Richard M. Tsai declares no conflict of interest.

Adam L. Boxer reports grants from NIH during preparation of this paper. He also reports research support from BMS, Forum, Cortice, Genentech, TauRx, and Eli Lilly, and personal fees from Ipierian, Asceneuron, and Isis, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.••
    Seltman R, Matthews B. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26:841–70. Excellent review article of FTLD syndromes. PubMedCrossRefGoogle Scholar
  2. 2.
    Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011;134:2456–77.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Gorno-Tempini ML, HIllis A, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Armstrong M, Litvan I, Lang A, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszeweski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394–400.PubMedCrossRefGoogle Scholar
  7. 7.
    Brooks B, Miller R, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Ringholz G, Appel S, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586.PubMedCrossRefGoogle Scholar
  9. 9.
    Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343.PubMedCrossRefGoogle Scholar
  11. 11.
    US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/show/NCT00382824. Accessed 23 Jul 2014.
  12. 12.
    Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:93107.CrossRefGoogle Scholar
  13. 13.
    Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–85.PubMedCrossRefGoogle Scholar
  14. 14.
    Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatr. 2007;15:84–7.CrossRefGoogle Scholar
  15. 15.
    Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int. 2013;13:506–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26(3):404–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103(2):123–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Diehl-Schmid J, Förstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatr. 2008;23:754–9.CrossRefGoogle Scholar
  21. 21.
    Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21:164–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211–7.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.••
    Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimer Dis. 2011;23:749–59. First large randomized, double-blind, controlled trial of memantine in FTD patients that did not reach primary endpoints. Google Scholar
  24. 24.••
    Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149–56. Large multi-center, randomized, double-blind, controlled therapeutic trial demonstrating memantine lack of efficacy. PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hermann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatr. 2012;20:789–97.CrossRefGoogle Scholar
  26. 26.
    Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler. 2007;8:189–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Prodan CI, Monnon M, Ross ED. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry. 2009;80:1416–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17:267–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavioral symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognitive in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharamcology (Berl). 2004;172:400–8.CrossRefGoogle Scholar
  33. 33.
    Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemoporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Curtis RC, Resch DS. Case of pick’s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000;20:384–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Fellgiebel A, Müller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Reeves RR, Perry CL. Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. J Clin Psychopharmacol. 2013;33:145–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008;69:1981–2.PubMedCrossRefGoogle Scholar
  39. 39.
    Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatr. 2003;18:67–72.CrossRefGoogle Scholar
  40. 40.•
    Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11: CD006625. doi: 10.1002/14651858.CD006625.pub3. Meta-Analysis of side effect and efficacy profile of many antipsychotics.PubMedGoogle Scholar
  41. 41.
    Mioshi E, Foxe D, Leslie F, et al. The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:68–73.PubMedCrossRefGoogle Scholar
  42. 42.
    Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22.PubMedCrossRefGoogle Scholar
  43. 43.
    Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–8.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Poetter CE, Stewart JT. Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. J Clin Psychopharmacol. 2012;31:137–8.CrossRefGoogle Scholar
  45. 45.
    Fleisher A, Truran D, Mai J, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011;77:1263–71.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Cruz M, Marinho V, Fontenelle LF, et al. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol. 2008;21:104–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Nestor PJ. Reversal of abnormal eating and drinking behavior in a frontotemporal lobar degeneration patient using low-dose topiramate. J Neurol Neurosurg Psychiatry. 2012;83:349–50.PubMedCrossRefGoogle Scholar
  48. 48.
    Singam C, Walterfang M, Mocellin R, et al. Topiramate for abnormal eating behavior in frontotemporal dementia. Behav Neurol. 2013;27:285–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Shinagawa S, Tsuno N, Nakayama K. Managing abnormal eating behaviors in frontotemporal lobar degeneration in patients with topiramate. Psychogeriatrics. 2013;13:58–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behavior in frontotemporal dementia. Brain. 2011;134:2493–501.PubMedCrossRefGoogle Scholar
  51. 51.
    Sha SJ, Boxer A. Treatment implications of C9ORF72. Alzheiemers Res Ther. 2012;4:46.CrossRefGoogle Scholar
  52. 52.
    Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropatholgoical featuers of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2011;82:196–203.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    DeJesus-Hernandez M, Mackenzie IR, et al. Expanded GGGC CC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.Google Scholar
  54. 54.
    Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68. PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.PubMedCrossRefGoogle Scholar
  56. 56.
    Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.PubMedCrossRefGoogle Scholar
  57. 57.
    Klawans Jr HL, Ringel SP. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol. 1971;5(2):115–29.PubMedCrossRefGoogle Scholar
  58. 58.
    Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55(8):1099–102.PubMedCrossRefGoogle Scholar
  59. 59.
    Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17(6):1255–64.PubMedCrossRefGoogle Scholar
  60. 60.•
    Kortte K, Rogalski E. Behavioural interventions for enhancing life participation in behavioral variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatr. 2013;25:237–45. Review of non-pharmacological interventions for FTD patients.CrossRefGoogle Scholar
  61. 61.
    US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/show/NCT01835665. Accessed 22 Aug 2014.
  62. 62.
    US National Institute of Health Clinical Trials Registry 2013. Available at http://www.clinicaltrials.gov/ct2/show/NCT02149160. Accessed 22 Aug 2014.
  63. 63.
    US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/ct2/show/NCT01626378. Accessed 23 Jul 2014.
  64. 64.
    Höglinger GU, Huppertz HJ, Wagenpfeil S, TAUROS MRI Investigators, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014;29(4):479–87.PubMedCrossRefGoogle Scholar
  65. 65.
    Tolosa E, Litvan I, Höglinger GU, TAUROS Investigators, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–14.PubMedCrossRefGoogle Scholar
  67. 67.••
    Boxer A, Lang A, Grossman M, AL-108-231 investigators. Davunetide in patients with progressive supranuclear palsy: a randomized, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13:676–85. Largest clinical trial of PSP to date. PubMedCrossRefGoogle Scholar
  68. 68.
    US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/ct2/show/NCT02133846. Accessed 23 Jul 2014.
  69. 69.
    Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415–28.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r(GGGG CC)-associated defects in c9FTD/ALS. Neuron. 2014. doi: 10.1016/j.neuron.2014.07.041.

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations